Comparative Pharmacology
Head-to-head clinical analysis: DIGOXIN PEDIATRIC versus LANOXIN PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIGOXIN PEDIATRIC versus LANOXIN PEDIATRIC.
DIGOXIN PEDIATRIC vs LANOXIN PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-potassium ATPase, increasing intracellular sodium, which promotes calcium influx via sodium-calcium exchanger, enhancing cardiac contractility. Also increases vagal tone, slowing AV conduction.
Inhibition of Na+/K+ ATPase leading to increased intracellular calcium and positive inotropy.
For pediatric patients, digoxin pediatric dosing is weight-based; no standard adult dose. Typical pediatric loading dose: 10-12 mcg/kg orally divided every 6-8 hours, with maintenance: 5-10 mcg/kg/day divided every 12 hours. For infants <1 month, loading: 10-15 mcg/kg, maintenance: 4-6 mcg/kg/day. For children 1-24 months, loading: 15-20 mcg/kg, maintenance: 5-8 mcg/kg/day. For children >2 years, loading: 10-15 mcg/kg, maintenance: 3-5 mcg/kg/day.
Adult: Oral loading dose 0.75-1.5 mg in divided doses over 24-48 hours. Maintenance: 0.125-0.5 mg once daily. Intravenous: Loading dose 0.5-1 mg over 10-20 minutes, then maintenance 0.125-0.5 mg once daily.
None Documented
None Documented
Terminal elimination half-life in neonates is 35-70 hours, infants 18-30 hours, children 12-30 hours, and adults 36-48 hours; prolonged in renal impairment and hypothyroidism.
Terminal elimination half-life is 36-48 hours in adults with normal renal function; prolonged to 3.5-5 days in anephric patients due to reduced renal clearance.
Renal excretion accounts for 50-70% of elimination as unchanged drug; biliary/fecal excretion accounts for 30-40%, primarily as metabolites; enterohepatic recirculation occurs.
Renal excretion of unchanged drug accounts for 60-80% of elimination; nonrenal clearance is 20-40% (biliary/fecal).
Category A/B
Category C
Cardiac Glycoside
Cardiac Glycoside